Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Timothy J Hobday

Showing results (61-70 of 71) with videos related to

Pageof 8
Sort By:
Breast Cancer Research and Treatment|April 28, 2017
Effects of metformin versus placebo on vitamin B12 metabolism in non-diabetic breast cancer patients in CCTG MA.32Ana Elisa Lohmann, Mira F Liebman, William Brien, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 20, 2019
Dietary Supplement Use During Chemotherapy and Survival Outcomes of Patients With Breast Cancer Enrolled in a Cooperative Group Clinical Trial (SWOG S0221)Christine B Ambrosone, Gary R Zirpoli, Alan D Hutson, et al.
Breast Cancer Research and Treatment|July 19, 2011
Genetic predictors of taxane-induced neurotoxicity in a SWOG phase III intergroup adjuvant breast cancer treatment trial (S0221)Lara E Sucheston, Hua Zhao, Song Yao, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 6, 2012
TBCRC 001: randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancerLisa A Carey, Hope S Rugo, P Kelly Marcom, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 26, 2014
SWOG S0221: a phase III trial comparing chemotherapy schedules in high-risk early-stage breast cancerGeorge T Budd, William E Barlow, Halle C F Moore, et al.
Journal of the National Cancer Institute|March 6, 2015
Effect of metformin vs placebo on and metabolic factors in NCIC CTG MA.32Pamela J Goodwin, Wendy R Parulekar, Karen A Gelmon, et al.
Journal of the National Cancer Institute|April 3, 2020
Physical Activity Before, During, and After Chemotherapy for High-Risk Breast Cancer: Relationships With SurvivalRikki A Cannioto, Alan Hutson, Shruti Dighe, et al.
NPJ Breast Cancer|June 9, 2021
Effect of metformin versus placebo on metabolic factors in the MA.32 randomized breast cancer trialPamela J Goodwin, Ryan J O Dowling, Marguerite Ennis, et al.
JAMA|May 24, 2022
Effect of Metformin vs Placebo on Invasive Disease-Free Survival in Patients With Breast Cancer: The MA.32 Randomized Clinical TrialPamela J Goodwin, Bingshu E Chen, Karen A Gelmon, et al.
JAMA Oncology|March 9, 2023
Evaluation of Alisertib Alone or Combined With Fulvestrant in Patients With Endocrine-Resistant Advanced Breast Cancer: The Phase 2 TBCRC041 Randomized Clinical TrialTufia C Haddad, Vera J Suman, Antonino B D'Assoro, et al.
Pageof 8

Showing results (61-70 of 71) with videos related to

Sort By:
Pageof 8
Breast Cancer Research and Treatment|April 28, 2017
Effects of metformin versus placebo on vitamin B12 metabolism in non-diabetic breast cancer patients in CCTG MA.32Ana Elisa Lohmann, Mira F Liebman, William Brien, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 20, 2019
Dietary Supplement Use During Chemotherapy and Survival Outcomes of Patients With Breast Cancer Enrolled in a Cooperative Group Clinical Trial (SWOG S0221)Christine B Ambrosone, Gary R Zirpoli, Alan D Hutson, et al.
Breast Cancer Research and Treatment|July 19, 2011
Genetic predictors of taxane-induced neurotoxicity in a SWOG phase III intergroup adjuvant breast cancer treatment trial (S0221)Lara E Sucheston, Hua Zhao, Song Yao, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 6, 2012
TBCRC 001: randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancerLisa A Carey, Hope S Rugo, P Kelly Marcom, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 26, 2014
SWOG S0221: a phase III trial comparing chemotherapy schedules in high-risk early-stage breast cancerGeorge T Budd, William E Barlow, Halle C F Moore, et al.
Journal of the National Cancer Institute|March 6, 2015
Effect of metformin vs placebo on and metabolic factors in NCIC CTG MA.32Pamela J Goodwin, Wendy R Parulekar, Karen A Gelmon, et al.
Journal of the National Cancer Institute|April 3, 2020
Physical Activity Before, During, and After Chemotherapy for High-Risk Breast Cancer: Relationships With SurvivalRikki A Cannioto, Alan Hutson, Shruti Dighe, et al.
NPJ Breast Cancer|June 9, 2021
Effect of metformin versus placebo on metabolic factors in the MA.32 randomized breast cancer trialPamela J Goodwin, Ryan J O Dowling, Marguerite Ennis, et al.
JAMA|May 24, 2022
Effect of Metformin vs Placebo on Invasive Disease-Free Survival in Patients With Breast Cancer: The MA.32 Randomized Clinical TrialPamela J Goodwin, Bingshu E Chen, Karen A Gelmon, et al.
JAMA Oncology|March 9, 2023
Evaluation of Alisertib Alone or Combined With Fulvestrant in Patients With Endocrine-Resistant Advanced Breast Cancer: The Phase 2 TBCRC041 Randomized Clinical TrialTufia C Haddad, Vera J Suman, Antonino B D'Assoro, et al.
Pageof 8